A Study of LY3437943 in Postmenopausal Female Participants Who Are Overweight or Obese
Status:
Active, not recruiting
Trial end date:
2024-07-05
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to determine the effect of LY3437943 when administered
subcutaneously on the levels of combined oral contraceptive (COC) ethinyl estradiol and
drospirenone in the blood stream in postmenopausal female participants who are overweight or
obese. The safety and tolerability of LY3437943 when administered with COC will also be
evaluated. This study will last up to approximately 29 weeks for each participant.